The EINSTEIN CYP Cohort Study Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism Using a Strong CYP 3A4 Inducer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary)
Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
Focus Pharmacodynamics; Pharmacokinetics
Acronyms EINSTEIN-CYP
Sponsors Bayer

Most Recent Events

01 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
10 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
10 Jan 2011 Planned end date changed from Mar 2011 to Jun 2011 as reported by ClinicalTrials.gov.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight